Login / Signup

Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration.

Stephen J FreedlandRickard SandinJanvi SahBirol EmirQiao MuAnna RatiuAgnes HongLucile SerfassScott T Tagawa
Published in: Cancer medicine (2021)
Most patients with mCSPC initiating ADT received ADT-only or ADT + NSAA, despite the emergence of docetaxel and novel hormonal therapies. Even in the most recent period (2017 to early 2018), only 24% of men received intensified therapy with agents known to prolong survival versus ADT-only. These data in real-world clinical practice suggest substantial room for improved outcomes in patients with mCSPC.
Keyphrases